Drugs / KAT-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05603572 | Nov 2022 → Nov 2027 | fibrolamellar hepatocellular carcinoma | Primocure Pharma | Suspended | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KAT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05603572 ↗ |
| Route | Oral | “Oral administration (KAT-101) taken once per day” NCT05603572 ↗ |